Phase I/II trial of a long peptide vaccine (LPV7) plus toll-like receptor (TLR) agonists with or without incomplete Freund’s adjuvant (IFA) for resected high-risk melanoma
Sapna P. Patel(JSS Dental College and Hospital), Craig L. Slingluff(University of Virginia Health System)
Cited by 61
Related Papers
First-in-Class ERK1/2 Inhibitor Ulixertinib (BVD-523) in Patients with MAPK Mutant Advanced Solid Tumors: Results of a Phase I Dose-Escalation and Expansion Study
|Cancer Discovery|2017|418
Conserved Interferon-γ Signaling Drives Clinical Response to Immune Checkpoint Blockade Therapy in Melanoma
|Cancer Cell|2020|379
Meta-analysis in metastatic uveal melanoma to determine progression free and overall survival benchmarks: an international rare cancers initiative (IRCI) ocular melanoma study
|Annals of Oncology|2019|282
Recommendations from the iSBTc-SITC/FDA/NCI Workshop on Immunotherapy Biomarkers
|Clinical Cancer Research|2011|109